Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth ...

Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). "This medication has a novel ...

Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory ...

The US Food and Drug Administration (FDA) has approved the combination of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) for treatment of adults with chronic inflammatory ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, ...